IDiyas

For the Inventor, By the Inventor

Leverkusen, Germany

Sarah Anna Liesa Johannes

USPTO Granted Patents = 12 

 

Average Co-Inventor Count = 19.0

ph-index = 3

Forward Citations = 32(Granted Patents)


Location History:

  • Duesseldorf, DE (2021)
  • Düsseldorf, DE (2023)
  • Leverkusen, DE (2022 - 2024)
  • Hilden, DE (2024)

Company Filing History:

goldMedal10 out of 12,157 
 
Bayer Aktiengesellschaft
 patents
silverMedal10 out of 378 
 
Bayer Pharma Aktiengesellschaft
 patents
bronzeMedal9 out of 443 
 
The Broad Institute, Inc.
 patents
4. 1 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 2021-2025

Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents
1. 12398120 - Substituted hydantoinamides as ADAMTS7 antagonists (2025-08-26),
2. 12152041 - Macrocyclic fluorine substituted indole derivatives (2024-11-26),
3. 12059472 - Prodrugs of cytotoxic active agents having enzymatically cleavable groups (2024-08-13),
4. 11891404 - Substituted macrocyclic indole derivatives (2024-02-06),
5. 11685714 - Prodrugs of cytotoxic active agents having enzymatically cleavable groups (2023-06-27),
6. 11492358 - Macrocyclic indole derivatives (2022-11-08),
7. 11478451 - Macrocyclic chlorine substituted indole derivatives (2022-10-25),
8. 11447504 - Macrocyclic chlorine substituted indole derivatives (2022-09-20),
9. 11440923 - Substituted macrocyclic indole derivatives (2022-09-13),
10. 11401278 - Macrocyclic indole derivatives (2022-08-02),
11. 11286263 - Macrocyclic fluorine substituted indole derivatives (2022-03-29),
12. 10981932 - Macrocyclic indole derivatives (2021-04-20),

Title: Sarah Anna Liesa Johannes: Innovating Cancer Treatment with Clever Prodrug Design

Introduction:

Sarah Anna Liesa Johannes is a pioneering inventor based in Hilden, Germany, with a keen focus on developing innovative prodrugs for more effective cancer treatment.

Latest Patents:

With a patent titled "Prodrugs of cytotoxic active agents having enzymatically cleavable groups," Sarah's invention introduces novel prodrugs with a unique asparagine derivative cleavage site for tumor-associated proteases like legumain. This design allows for precise delivery of cytotoxic drugs to tumor cells, enhancing treatment efficacy while minimizing side effects on healthy tissues.

Career Highlights:

Sarah has made significant contributions to the field of oncology through her work at renowned companies like Bayer Aktiengesellschaft and Bayer Pharma Aktiengesellschaft. Her dedication to revolutionizing cancer therapy has garnered recognition within the pharmaceutical industry.

Collaborations:

Throughout her career, Sarah has collaborated with esteemed professionals in the field, including colleagues such as Hans-Georg Lerchen and Anne-Sophie Rebstock. Together, they have worked towards developing cutting-edge solutions for combatting hyperproliferative and angiogenic disorders, particularly in the realm of cancer treatment.

Conclusion:

In conclusion, Sarah Anna Liesa Johannes stands as a beacon of innovation in the realm of cancer therapeutics, leveraging her expertise to pioneer novel prodrug designs that hold immense promise for improving patient outcomes. Her relentless pursuit of excellence underscores her commitment to advancing the field of oncology and revolutionizing the way we approach cancer treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…